Article By:
ChinaBio® Today
Sunday, January 18, 2015 8:18 PM EDT
Guangzhou Baiyunshan Pharma (HK: 874) will raise $1.6 billion in a secondary offering, which it will use for various corporate initiatives, including expanding its China's online drug selling effort. Yunfeng, the private equity firm co-founded by Alibaba's Jack Ma is an investor.